ALNY
HEALTHCAREAlnylam Pharmaceuticals Inc
$303.00+1.89 (+0.63%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ALNY Today?
No stock-specific AI insight has been generated for ALNY yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$250.35$495.55
$303.00
Fundamentals
Market Cap$40.5B
P/E Ratio76.3
EPS$3.97
Dividend Yield—
Dividend / Share—
ROE0.9%
Profit Margin0.1%
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding133.5M
ALNY News
20 articles- A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price WeaknessYahoo Finance·May 8, 2026
- Alnylam to Webcast Presentations at Upcoming Investor ConferencesYahoo Finance·May 7, 2026
- MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant AwardYahoo Finance·May 7, 2026
- Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CMYahoo Finance·May 4, 2026
- Alnylam Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearYahoo Finance·May 3, 2026
- Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair ValueYahoo Finance·May 1, 2026
- Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y GrowthYahoo Finance·May 1, 2026
- Discover 3 Stocks That Might Be Trading Below Estimated ValueYahoo Finance·May 1, 2026
- Alnylam Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·Apr 30, 2026
- Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%Yahoo Finance·Apr 30, 2026
- Alnylam (ALNY) Q1 2026 Earnings TranscriptMotley Fool·Apr 30, 2026
- Alnylam Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·Apr 30, 2026
- Alnylam (ALNY) Reports Q1 Earnings: What Key Metrics Have to SayYahoo Finance·Apr 30, 2026
- Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·Apr 30, 2026
- Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period ProgressYahoo Finance·Apr 30, 2026
- 3 Companies That May Be Priced Below Their Estimated ValueYahoo Finance·Apr 30, 2026
- 3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%Yahoo Finance·Apr 29, 2026
- Alnylam (ALNY) Q1 Earnings Preview: What You Should Know Beyond the Headline EstimatesYahoo Finance·Apr 29, 2026
- 3 Stocks That May Be Trading Below Their Estimated Value In April 2026Yahoo Finance·Apr 29, 2026
All 20 articles loaded
Price Data
Open$301.57
Previous Close$301.11
Day High$306.03
Day Low$298.96
52 Week High$495.55
52 Week Low$250.35
52-Week Range
$250.35$495.55
$303.00
Fundamentals
Market Cap$40.5B
P/E Ratio76.3
EPS$3.97
Dividend Yield—
Dividend / Share—
ROE0.9%
Profit Margin0.1%
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding133.5M
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—